NovioSense is pioneering non-invasive glucose monitoring technology aimed at providing a painless and unobtrusive alternative to traditional finger-prick methods. The company operates in the healthcare sector, specifically targeting diabetic patients who require regular glucose monitoring. NovioSense's core product is a tear fluid sensor that measures glucose levels with clinically relevant accuracy, utilizing wireless data and power to provide continuous monitoring. This innovative approach not only alleviates the discomfort associated with finger-prick tests but also offers a more convenient and less intrusive solution for diabetes management.

The company serves diabetic patients, healthcare providers, and potentially sports professionals, as indicated by their collaboration with TuDelft and Adidas to develop sensors for preventing sports injuries. NovioSense operates primarily in the medical device market, focusing on diabetes care and sports health.

NovioSense's business model revolves around the development, production, and sale of their glucose monitoring devices. Revenue is generated through the sale of these devices to end-users and healthcare institutions. Additionally, the company may explore partnerships and collaborations with other healthcare and technology firms to expand its market reach and application areas.

Keywords: non-invasive, glucose monitoring, tear fluid sensor, diabetes management, wireless data, healthcare, medical device, diabetic patients, sports health, clinical accuracy.